Stock listing

Frankfurt:PBDA Protalix BioTherapeutics, Inc. Aktie

German listing (Frankfurt) of Protalix BioTherapeutics, Inc. · home listing NYSE American:PLX

Follow Protalix BioTherapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:PBDA

€2.26 EUR +0.05 (+2.5%)

Close on Oct 30, 2026

Day range
€2.26 – €2.28 EUROct 30, 2026
Market cap
€181.7M EURAt the close on Oct 30, 2026 · price × 80.57M shares outstanding
Protalix BioTherapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:PLX · Home$2.56 USD-0.03 (-1.2%)726,273$2.60$2.62$2.54$2.59Close on Nov 2, 2026
Frankfurt:PBDA€2.255 EUR+0.055 (+2.5%)—€2.27€2.28€2.255€2.20Close on Oct 30, 2026
Ticker
Frankfurt:PBDA
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Protalix Biotherapeutics (NYSE American: PLX) Q2 2026 Earnings Call

    Wed, Aug 12, 2026 · 8:00 AM ET

    Watch Transcript

  • Protalix Biotherapeutics (NYSE American: PLX) Q1 2026 Earnings Call

    Wed, May 13, 2026 · 8:00 AM ET

    Watch Transcript

  • Protalix Biotherapeutics (NYSE American: PLX) Q4 2025 Earnings Call

    Wed, Mar 18, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026

Nov 3, 2026

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Aug 12, 2026

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Aug 5, 2026

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Mar 18, 2026

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Mar 11, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Mar 9, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 30, 2026

All Protalix BioTherapeutics, Inc. news

Decks

Protalix BioTherapeutics, Inc. on 6ix

News releases
16 in the last 12 months · 26 in all · newest Nov 3, 2026 · oldest 2025
Calls
23 calls with a replay · 23 with a transcript · latest Aug 12, 2026
Decks
22 decks · latest August 2026

Where Protalix BioTherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:PLX · Home listingNYSE AmericanUnited StatesUSD
gettex:PBDAgettexGermanyEUR
BOATS:PLXBOATSUnited StatesUSD
LS Exchange:A2PWSLLS ExchangeGermanyEUR
Lang & Schwarz:A2PWSLLang & SchwarzGermanyEUR
Frankfurt:PBDA · This pageFrankfurtGermanyEUR
Stuttgart:PBDAStuttgartGermanyEUR
Dusseldorf:PBDADusseldorfGermanyEUR
Munich:PBDAMunichGermanyEUR
Tradegate:PBDATradegateGermanyEUR

Log in to ask 6ix AI your own questions about Protalix BioTherapeutics, Inc.